Login to Your Account

Other News To Note

Wednesday, November 9, 2011
• Amakem NV, of Diepenbeek, Belgium, reported data showing that AMA0247, a selective Rho kinase inhibitor, was effective in inhibiting the inflammatory reaction in the lungs, as measured by neutrophil infiltration, but had no effect on blood pressure or heart rate in a smoking mouse model for chronic obstructive pulmonary disease. AMA0247 was derived from the firm's Localized Drug Action platform.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription